The current understanding on the impact of KRAS on colorectal cancer

Mingjing Meng; Keying Zhong; Ting Jiang; Zhongqiu Liu; Hiu Yee Kwan; Tao Su

doi:10.1016/j.biopha.2021.111717

The current understanding on the impact of KRAS on colorectal cancer

Mingjing Meng, Keying Zhong, Ting Jiang, Zhongqiu Liu^*, Hiu Yee Kwan^*, Tao Su^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › peer-review

77 Citations (Scopus)

Abstract

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.

Original language	English
Article number	111717
Number of pages	13
Journal	Biomedicine and Pharmacotherapy
Volume	140
DOIs	https://doi.org/10.1016/j.biopha.2021.111717
Publication status	Published - Aug 2021

User-Defined Keywords

Colorectal cancer
KRAS
Mutation
Therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biopha.2021.111717

Cite this

@article{8b12924da225478ca802dd1bc03cc45d,

title = "The current understanding on the impact of KRAS on colorectal cancer",

abstract = "KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.",

keywords = "Colorectal cancer, KRAS, Mutation, Therapy",

author = "Mingjing Meng and Keying Zhong and Ting Jiang and Zhongqiu Liu and Kwan, {Hiu Yee} and Tao Su",

year = "2021",

month = aug,

doi = "10.1016/j.biopha.2021.111717",

language = "English",

volume = "140",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

}

TY - JOUR

T1 - The current understanding on the impact of KRAS on colorectal cancer

AU - Meng, Mingjing

AU - Zhong, Keying

AU - Jiang, Ting

AU - Liu, Zhongqiu

AU - Kwan, Hiu Yee

AU - Su, Tao

PY - 2021/8

Y1 - 2021/8

N2 - KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.

AB - KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.

KW - Colorectal cancer

KW - KRAS

KW - Mutation

KW - Therapy

U2 - 10.1016/j.biopha.2021.111717

DO - 10.1016/j.biopha.2021.111717

M3 - Journal article

SN - 0753-3322

VL - 140

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 111717

ER -

The current understanding on the impact of KRAS on colorectal cancer

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Fingerprint

Cite this